Abstract:Engineering immune cells to target cancer is a rapidly advancing technology. The first commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for hematologic malignancies. However, solid tumors pose a greater challenge for cellular therapy, in part because suitable cancer-specific antigens are more difficult to identify and surrounding healthy tissues are harder to avoid. In addition, impaired trafficking of immune cells to solid tumors, the harsh immune-inhibitory microenvironment, and variable antigen density and presentation help tumors evade immune cells targeting cancer-specific antigens. To overcome these obstacles, T cells are being engineered to express defined T-cell receptors (TCR). Given that TCRs target intracellular peptides expressed on tumor MHC molecules, this provides an expanded pool of potential targetable tumor-specific antigens relative to the cell-surface antigens that are targeted by CAR T cells. The affinity of TCR T cells can be tuned to allow for better tumor recognition, even with varying levels of antigen presentation on the tumor and surrounding healthy tissue. Further enhancements to TCR T cells include improved platforms that enable more robust cell expansion and persistence; coadministration of small molecules that enhance tumor recognition and immune activation; and coexpression of cytokine-producing moieties, activating coreceptors, or mediators that relieve checkpoint blockade. Early-phase clinical trials pose logistical challenges involving production, large-scale manufacturing, and more. The challenges and obstacles to successful TCR T-cell therapy, and ways to overcome these and improve anticancer activity and efficacy, are discussed herein.

Genetically engineered T cells for cancer immunotherapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy

Advances in Engineering Cells for Cancer Immunotherapy

TCR engineered T cells for solid tumor immunotherapy

Clinical application of genetically modified T cells in cancer therapy

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Improving the efficacy and safety of engineered T cell therapy for cancer.

Genetic engineering of T cells for immunotherapy

Engineered T Cell Receptor for Cancer Immunotherapy

Engineered T Cells and Their Therapeutic Applications in Autoimmune Diseases

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy

Synthetic immunology: T-cell engineering and adoptive immunotherapy

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

T-cell receptor-engineered T cells for cancer treatment: current status and future directions